Edwards Lifesciences presented its focused strategy for long-term sustainable growth and provided financial guidance at its annual investor conference on December 4, 2024. The company projected 2025 total company sales of $5.6 billion to $6.0 billion, representing 8% to 10% constant currency growth.
Key growth drivers highlighted include Transcatheter Aortic Valve Replacement (TAVR) with projected sales of $4.1 billion to $4.4 billion (5% to 7% constant currency growth), and Transcatheter Mitral and Tricuspid Therapies (TMTT) with expected sales of $500 million to $530 million (50% to 60% constant currency growth). Surgical sales are anticipated to achieve mid-single digit constant currency growth.
The company also maintained its adjusted gross profit margin guidance of 78% to 79% and adjusted operating margin of 27% to 28% for 2025. Adjusted earnings per share are projected to be between $2.40 and $2.50. Edwards emphasized future opportunities in Structural Heart Failure and Aortic Regurgitation, driven by its technology pipeline and clinical evidence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.